key: cord-0896557-g6kpnh87
authors: Vaughan, A. M.; Duffell, E. F.; Friedl, G. S.; Lemos, D. S.; Funk, T.; Nardone, A.; Valenciano, M.; Subissi, L.; Bergeri, I.; Broberg, E.; Penttinen, P.; Pebody, R.; Keramarou, M.
title: Seroprevalence of SARS-CoV-2 antibodies prior to the widespread introduction of vaccine programmes in the WHO European Region, January - December 2020: a systematic review
date: 2021-12-05
journal: nan
DOI: 10.1101/2021.12.02.21266897
sha: b36bd4c840e60a503869820f14f24ac3dfffb7ff
doc_id: 896557
cord_uid: g6kpnh87

Seroprevalence surveys are essential to assess the age-specific prevalence of pre-existing cross-reactive antibodies in the population with the emergence of a novel pathogen; to measure population cumulative seroincidence of infection, and to contribute to estimating infection severity. With the emergence of SARS-CoV-2, ECDC and WHO Regional Office for Europe have supported Member States in undertaking standardized population-based SARS-CoV-2 seroprevalence surveys across the WHO European Region. The objective of this study was to undertake a systematic literature review of SARS-CoV-2 population seroprevalence studies undertaken in the WHO European Region to measure pre-existing and cumulative seropositivity prior to the roll out of vaccination programmes. We systematically searched MEDLINE, ELSEVIER and the pre-print servers medRxiv and bioRxiv within the COVID-19 Global literature on coronavirus disease database using a predefined search strategy. We included seroepidemiology studies published before the widespread implementation of COVID-19 vaccination programmes in January 2021 among the general population and blood donors, at national and regional levels. Study risk of bias was assessed using a quality scoring system based on sample size, sampling and testing methodologies. Articles were supplemented with unpublished WHO-supported Unity-aligned seroprevalence studies and other studies reported directly to WHO Regional Office for Europe and ECDC. In total, 111 studies from 26 countries published or conducted between 01/01/2020 and 31/12/2020 across the WHO European Region were included. A significant heterogeneity in implementation was noted across the studies, with a paucity of studies from the east of the Region. Eighty-one (73%) studies were assessed to be of low to medium risk of bias. Overall, SARS-CoV-2 seropositivity prior to widespread community circulation was very low. National seroprevalence estimates after circulation started ranged from 0% to 51.3% (median 2.2% (IQR 0.7-5.2%); n=124), while sub-national estimates ranged from 0% to 52% (median 5.8% (IQR 2.3-12%); n=101), with the highest estimates in areas following widespread local transmission. The review found evidence of low national SARS-CoV-2 seroprevalence (<10%) across the WHO European Region in 2020. The low levels of SARS-CoV-2 antibody in most populations prior to the start of vaccine programmes highlights the critical importance of vaccinating priority groups at risk of severe disease while maintaining reduced levels of transmission to minimize population morbidity and mortality.

The novel virus, Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) was first identified in Wuhan, China in December 2019 and spread rapidly around the world. At that time, the transmissibility, population susceptibility, clinical spectrum and infection-severity were all unknown.

As of 5 November 2021, approximately 248 million confirmed cases and 5 million deaths have been reported globally, while in the WHO European Region, there have been 78 million cases and 1.4 million deaths (1, 2) . However, notified cases and deaths are an underestimate of the true number of infections for reasons including clinical presentation with a large proportion of asymptomatic or mildly symptomatic cases, testing and reporting strategies and health care seeking behaviour (3) .

Asymptomatic infection has been reported in many studies with the proportion ranging from 6 to 41% (4) (5) (6) , so a significant proportion of SARS-CoV-2 infections will be missed through case-based surveillance systems (7) .

As the majority of infected individuals have a detectable humoral immune response on average 10-14 days after symptom onset and most individuals seroconvert within 3-4 weeks of infection (8) , seroprevalence studies which measure SARS-CoV-2 antibodies can provide an important complement to routine surveillance, particularly as part of the assessment of novel emerging respiratory pathogens.

Seroprevalence surveys are essential to assess the age-specific prevalence of pre-existing cross-reactive antibodies in the population; to measure population age-specific cumulative seroincidence as the novel virus spreads and to contribute to estimating infection-severity.

Since the start of the COVID-19 pandemic, there has been a rapid accumulation of seroepidemiological studies describing the seroprevalence of SARS-CoV-2. This review aims to provide a comprehensive review of studies conducted in the WHO European Region between 1 January and 31 December 2020 in the general population, with the aim to synthesize evidence on the extent of transmission across the region and population immunity to this newly emerging infection before the start of the COVID-19 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) vaccination programmes. As SARS-CoV-2 continues to circulate widely, understanding the age-specific population seropositivity remains critical for policymakers and public health officials to make informed decisions on optimal public health interventions (9) .

We searched MEDLINE, WHO COVID, ELSEVIER and the pre-print servers medRxiv and bioRxiv within the WHO "COVID-19 Global literature on coronavirus disease" database on 21/10/2020 and 12/01/2021. The searches spanned the period 1 January -31 December 2020 and was not restricted by language. We supplemented these articles with WHO-supported Unity seroprevalence studies and unpublished studies reported to WHO Regional Office for Europe and ECDC. The selection process followed the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines (10) . The full search strategy, search terms as well as inclusion and exclusion criteria are described in Supplementary Material S1.

We combined the references from all databases, removed duplicates and imported the remaining articles into Rayyan software (11) for screening of titles and abstracts according to the inclusion and exclusion criteria (Supplementary Table S2 ). After the initial screening of title and abstracts, we assessed full-text publications for eligibility. At least two independent researchers extracted the eligible studies; a third researcher resolved any disagreements on assessment of eligibility or extraction. We extracted the following data: first author, publication date, country, region, period of study, population type, population age, sampling method, sample size, laboratory methods used, confirmatory testing, test performance, crude and adjusted point seroprevalence estimates, antibody type and analysis methodology. Comparison was made with weekly laboratory confirmed case and death reports. Data from pre-print articles and unpublished data included in this review were extracted and later updated if published article was available on 6 September 2021.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

We developed a quality assessment scoring system to assess the overall risk of bias of each study. The criteria included: a) the sampling frame (to assess representativeness of the general population); b) stratification (age, sex or population); c) recruitment method (random, convenience), d): adequacy of sample size, e): serological methods and validation; f) and statistical analyses (adjustment of results to account for the sensitivity and specificity of the test). A cumulative quality score classified the overall risk of bias of each study into high risk of bias (1) (2) (3) , medium risk of bias (4) (5) (6) or low risk of bias (>6).

See Supplementary Table S1 for more details on the quality criteria and Table 2 for scoring for each study. For the purposes of quality assessment, the threshold for acceptable test performance was ≥95% sensitivity and >97% specificity for laboratory assays and ≥90% sensitivity and >97% specificity for point-of-care tests (12) .

We used descriptive statistics to summarize results. We generated forest plots to display the data and explore variations according to specific characteristics, including time and population group. Correlation between cumulative incidence and cumulative deaths and seroprevalence estimates from studies of the general population was explored using Spearman's rank correlation. We compared seroprevalence estimates from studies of the general population and the cumulative incidence and deaths at the start of each study. Analyses were performed in Microsoft Excel (version 2016) and R version 4.0.4.

The literature search resulted in 4,063 studies. After deduplication, application of inclusion and exclusion criteria and supplementation with articles from other sources, a total of 111 studies were included in this review. Of these, 77 were published articles, 19 were preprints, nine were institutional reports, and six were studies were identified through reporting of unpublished results to WHO or ECDC.

See Figure 1 PRISMA flow diagram study selection.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Table 1 ). Fifty-six (50%) studies were aligned with the World Health Organization Unity population-based sero-epidemiological investigation criteria related to study design, data collection and analysis (2) .

The majority of studies (n=69, 62%) used non-random or convenience sampling of the population. Fortyone (37%) studies used random sampling, while one study did not report sampling methodology.

Characteristics and details of included studies are shown in Table 1 and Table 4 , respectively.

In total, 72 (65%) of the studies provided representative estimates from the general population, of which sample frames included 45 (41%) studies of household or community samples, 13 (12%) residual sera, 13 (12%) patients seeking healthcare for non-COVID-19 related issues, seven (6%) pregnant or parturient women. Sixteen (14%) studies sampled blood donors as a proxy for the general population while 23 (21%) sampled other or multiple populations. Studies were conducted at differing geographical levels within a country, including at the national level (n=33; 30%), regional level (n=27; 24%) and city or local level (n=50; 44%). One study reported both national and regional estimates (13) .

Over half of the studies used one serological assay (74; 67%) while 34 (31%) used at least two different assays. In 82 studies (74%), commercial assays from various sources were used, 20 (18%) studies used an in-house assay only and six studies (5%) used both a commercial and in-house developed assay. The test method was not reported in two studies. An Enzyme-linked Immunosorbent assay (ELISA) was the method most commonly employed (n=55, 50%), followed by Chemiluminescent immunoassay (CLIA) or Chemiluminescence Microparticle Immunoassay (CMIA) (n=42, 38%) and lateral flow immunoassays (LFAs) (n=25, 23%). Seventeen studies (15%) used LFAs exclusively. Ten studies (9%)

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) employed in-house microneutralization assays to assess the neutralizing ability of SARS-CoV-2 antibodies.

Of 90 studies that used a commercial assay, 33 studies (37%) reported the use of tests with acceptable sensitivity and specificity. Of those that independently validated assay performance (n=41, 46%), 14 (34%) reported acceptable sensitivity and specificity, while 27 (66%) did not meet these thresholds. Of the 20 studies that used an in-house assay, nine (45%) reported an acceptable test performance, four (20%) performed below these thresholds and seven (35%) did not report on test performance. The majority of studies (n=83, 75%) did not report adjustment for test sensitivity or specificity in their analysis.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted December 5, 2021. ; https://doi.org/10.1101/2021.12.02.21266897 doi: medRxiv preprint Based on our quality scoring system (Supplementary Table S3) , 81 studies (73%) were of high or medium quality reflecting a low or medium risk of bias, respectively (medium quality: n=40, 36%; high quality n=41, 37%). A total of 24 studies (22%) were determined to be at high risk of bias, largely due to non-random sampling frame, weak representativeness of the general population or lack of adjustment for sampling bias or test performance. A quality assessment was not performed for unpublished studies.

Seroprevalence estimates (n=88) from national studies ranged from 0% (CI: 0.0-0.7) in Finland in May A total of 45 studies provided seroprevalence estimates (n=105) from community or household samples and 39 studies (87%) were found to be of high or medium quality. Seroprevalence estimates ranged from 0% (CI: 0-0.7%) in Finland in May and to 51.3% in December 2020 in Georgia (15) (median 2.6% (IQR 0.5-10%) n=105) (Supplementary Figure S1 ).

Thirteen studies screened residual clinical samples (29-42) between February and November 2020, of which nine (70%) were of high or medium quality. Seroprevalence estimates (n=34) in this population varied across countries ranging from 0% (CI 0-0.23) in Greece in March to 18.7% (CI 16.7-23.3%) in Sweden in June (median 4.5% (IQR 3.5-5.9%); n=34) (Supplementary Figure S2a) .

Eighteen studies (17%) utilized blood donors as a proxy for the general population between February and December 2020, of which 16 were of high or medium quality. Seroprevalence estimates (n=42) in blood donors varied across countries, ranging from 0.4% in Germany between March and June (17) to . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) 30% in Tensta (Stockholm) following a period of high incidence in June (18) (median 5.8% (IQR 2.1- Figure S2b) .

Eight studies investigated the seroprevalence of SARS-CoV-2 in pregnant or parturient women, reporting estimates ranging from 2.6% (CI 1.7-4%) and 14.3% between March and June 2020 (median 6.9% (IQR 5.1-12%); n=8) (19-25) (Supplementary Figure S2c Forty-four (41%) studies reported seroprevalence estimates stratified by age. Seroprevalence estimates varied considerably across age groups and estimates tended to be lower in children (<18 years) (32-34) and older age groups (>60 years) (32, 35-40). Whilst a number of studies reported a high seroprevalence in older age groups (>55 years) (36, 37, 41-46), some studies also reported a higher seroprevalence in younger age groups (<40 years) (33, 46-48). In studies that reported seroprevalence estimates by sex, similar seroprevalence results were observed between females and males with the exception of a study in Italy (45), Russian Federation (49) and Kyrgyzstan (34) which each found a higher seroprevalence in females.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

A number of studies provided seroprevalence estimates prior to, or at the early stages of the epidemic in the country (Supplementary Figure S3 ). Of these, overall study estimates were largely below 10%, however higher seroprevalence was noted in a number of population-specific, regional or local studies (29, 36, 43, 50-54), with suggestion of earlier undetected transmission in some countries (24, 26, 34, 55). A total of 16 studies reported seroprevalence estimates spanning multiple timepoints or stages of the epidemic (14, 15, 27, 31, 32, 47, [56] [57] [58] [59] [60] [61] [62] [63] [64] [65] [66] [67] [68] [69] [70] [71] [72] [73] . In a serial cross-sectional study in France (61), residual blood sampled before, during and after a national lockdown showed a seroprevalence of 0.41%, 4.14%, and 4.93%, respectively. In Georgia, in a community sample, an increase in seroprevalence from 0-1.3%

in August 2020 to 35-51.3% in the same regions in December 2020 was noted (15) . A seroprevalence study in blood donors conducted in Milan between February and April 2020 during a period of intense transmission found an increase in seroprevalence from 2.7% (95% 0.3-6.0%) to 5.2% (95% 2.4-9.0), with an adjusted rate of increase in antibodies (IgG) of 2.7±1.3% per week as social distancing measures were gradually implemented (58). While in Finland, weekly testing of blood donors from April 2020 onwards showed a consistently low seroprevalence in the general population over time (0.28% (0.05-1.55) in early April 2020 to 0% (0-12.87) in late December 2020 (67).

The relationship between seroprevalence and reported SARS-CoV-2 laboratory confirmed cumulative case and deaths incidence was also explored. While seroprevalence from national studies correlated moderately with cumulative incidence (Spearman's rank correlation coefficient, 0·52) ( Figure 4a ), a stronger correlation was observed between seroprevalence estimates and cumulative SARS-CoV-2 deaths (Spearman's rank correlation coefficient, 0·754) ( Figure 4b ).

In this study we report the results of 111 studies, including 224 seroprevalence estimates from 26 countries in the WHO European Region undertaken until December 2020, prior to the implementation of national COVID-19 vaccine campaigns. A significant heterogeneity in implementation was noted across the studies, with a bias towards studies in high-income countries in Western Europe.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted December 5, 2021. ; https://doi.org/10.1101/2021.12.02.21266897 doi: medRxiv preprint

Overall, population-wide seroprevalence estimates were low (below 10%) across the Region early in 2020 before the onset of widespread community transmission and remained low across the Region throughout 2020, despite circulation of SARS-CoV-2 over this period. Higher estimates were observed at a regional or local level in populations that had experienced intense community transmission (up to 52%). Furthermore, a positive correlation between seroprevalence estimates and national cumulative incidence was observed, with a stronger correlation between seroprevalence and cumulative mortality. A number of studies reported low seroprevalence in younger and older age groups, a finding observed in other systematic reviews (74, 76, 78) . Such findings have important implications, as groups such as the elderly are at higher risk of severe outcome following infectionand lack of cross-protective immunity indicates that all age-groups will anticipate to see high infection attack rates without . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted December 5, 2021. ;  implementation of measures such as vaccination of priority groups, together with strengthening of public health and social measures to reduce SARS-CoV-2 transmission.

When reviewed alongside case notification data, seroprevalence estimates can provide greater insight into the local evolution of the pandemic. In this review, a positive correlation between seroprevalence estimates and national cumulative incidence in a number of countries was observed, suggesting that seroprevalence is a reflection of the duration and intensity of community transmission. It should be noted however that during the initial peak of infections in Europe in the spring of 2020, testing in many countries was not yet optimal and case notification data at this time are unlikely to provide a robust proxy for incidence in many instances. In line with this, several studies found seroprevalence estimates to be higher than the corresponding cumulative incidence of SARS-CoV-2 infections, suggesting a substantial under-ascertainment of infection through notifications, due to a number of factors including the asymptomatic or mild nature of disease, healthcare seeking behaviour, lack of testing capacity and testing and reporting strategies. Indeed, we also found a stronger association between seroprevalence and cumulative case mortality than cumulative case incidence, providing further evidence to support the suggestion of case under-ascertainment, as laboratory confirmed mortality surveillance for COVID-19 is likely to be more comprehensive.

The varying quality of studies in this review reflects the challenge of conducting seroepidemiological studies of high quality. Indeed, this review found that only 50% of all studies undertaken in the WHO European region in 2020 were aligned with the WHO Unity study initiative. Few of the national (n=5; 15%) or regional (n=2; 7%) studies were determined to be of high risk of bias, while 17 (34%) of studies conducted at a local level (cities or towns) were graded as such. This variation may be explained by the level of resources and epidemiological support available to studies conducted at the regional or national level.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted December 5, 2021. ;

The majority of studies identified in this review utilised convenience rather than random sampling, which may have reduced the true representativeness of the estimates derived, though such convenience sampling is likely to provide a good estimate of population exposure for widely circulating viral infections. Many studies also included individuals that were not fully representative of the population under study, which may have introduced bias. For example, this review included studies that explored seroprevalence in the general population by utilising various proxy populations such as blood donors and residual blood. Blood donors are known to differ from the general population in that they are often a young, healthy adult population selected on the basis of lack of recent infection (79) and seroprevalence may therefore be over or underestimated in this group. Residual sera, on the other hand, derives from individuals who have sought health care and may therefore have pre-existing comorbidities or be at higher risk of SARS-CoV-2 infection. However, we found that seroprevalence estimates for these distinct populations are in good agreement with the general population.

We also found that there was a high degree of heterogeneity across serological assays used. The majority of studies used commercial tests of varying sensitivity and specificity to detect SARS-CoV-2 targeted antibodies, although some of these assays have now been shown to have excellent performance (80, 81).

However, under half of studies performed independent validation of these kits with internal controls and serum panels and only 25% accounted for the sensitivity and specificity of the tests in their statistical analyses. As SARS-CoV-2 serological tests have been found to have variable test performance (80, 81), independent validation at local level in combination with use of an WHO International Standard and Reference Panel for anti-SARS-CoV-2 antibody has been widely promoted as part of the Solidarity II initiative (82, 83). Other options include the Joint Research Centre (84) reference materials for the quality control of SARS-CoV-2 antibody tests. Use of these materials will allow for the potential correction for sensitivity and specificity during the statistical analysis, would allow for more robust estimates and greater comparability among countries in the region.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted December 5, 2021. ;  Overall, the findings of this review highlight the need for international collaboration to standardise approaches and support countries in conducting robust comparable studies. WHO, in collaboration with technical partners, has developed the Unity studies (2)(90), a global seroepidemiology standardization initiative for COVID-19, which aims to increase quality evidence-based knowledge in country and regions for action through the availability of standardized seroepidemiology investigation protocols and antibody assays. A primary aim of this global initiative is the provision of direct support to countries to develop country specific protocols, with particular attention provided to low-and middle-income countries (LMICs), and to support aggregation, comparison and analysis of robust Unity-aligned studies through strong coordination between WHO Country offices, Regional offices and Headquarters. A large proportion of the studies identified in this systematic review were conducted in Western European countries, with a relative scarcity of seroprevalence studies from other countries by the end of 2020, an observation noted in other systematic reviews (74) (75) (76) 78 ). This highlights the urgent need for enhanced capacity, the provision of additional support to LMICs and the sharing of information to address the gap in knowledge and tackle research inequity. To counteract the skewedness in the WHO European Region, the WHO Unity protocols have been widely promoted by WHO and ECDC and technical support has been provided to tailor the protocols to local contexts, together with laboratory and financial support to LMICs. In addition, WHO and ECDC jointly established a network of approximately 300 public health professionals to facilitate discussions in related to SARS-CoV-2 seroprevalence, promote timely sharing of results and knowledge and further build capacity in the WHO European Region.

This systematic review is the first in the WHO European region to describe the seroprevalence of SARS-CoV-2 in the first year of the pandemic, prior to the widespread implementation of vaccine programs nationally. In addition, with the inclusion of as yet unpublished data from LMICs, this review contributes to research equity across Member States income levels and provides a more representative overview of the situation in the WHO European Region than published studies alone. This review has some limitations. Firstly, there was significant heterogeneity among the studies, including sampling frame, . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted December 5, 2021. ;  population and stage of epidemic at time of serosurvey, which makes comparability across studies difficult. Due to such heterogeneity, we opted to not provide one pooled estimate nor conduct a metaanalysis as interpretation would be difficult and may not accurately reflect the picture in the WHO European Region. Secondly, while population-based serological surveys can provide a more accurate estimation of the overall rates of SARS-CoV-2 infection within a population, this approach does not consider antibody waning, which cannot be easily accounted for as antibody levels vary depending on disease severity (85) and longevity is expected to vary greatly across SARS-CoV-2 infected individuals (86). Finally, due to the rapid accumulation of data related to SARS-CoV-2 seroepidemiology and the advent of the 'preprint era', not all included studies have been published and may therefore be subject to change upon peer review.

As SARS-CoV-2 continues to circulate widely, understanding the population seropositivity remains critical for policymakers and public health officials to make informed decisions on optimal public health interventions, such as lifting or tightening of restrictions (9, 87). We found evidence that SARS-CoV-2 antibody seroprevalence across the WHO European Region was low prior to widespread circulation and remained low in the general population during 2020. This suggests that much of the population remained susceptible to infection prior to the implementation of national COVID-19 vaccine campaigns from early 2021 onwards. We also found variation in seroprevalence estimates between and within countries during 2020 with evidence of increased prevalence in areas following high levels of transmission and some association with incidence and mortality trends over time. It is clear that antibody-mediated 'herd immunity' through natural infection is not attainable in most countries and COVID-19 vaccines should continue to be distributed widely and equitably to protect priority groups and the wider population. In addition, all efforts must be also directed towards well-informed and evidence-based implementation and maintenance of non-pharmaceutical interventions at a local and national level to stem any future waves of the pandemic. As vaccine programs continue to be implemented more widely, seroprevalence . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted December 5, 2021. ; https://doi.org/10.1101/2021.12.02.21266897 doi: medRxiv preprint studies will be instrumental to evaluate both natural and vaccine derived immunity overtime to guide public health actions and decision making.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted December 5, 2021. ; https://doi.org/10.1101/2021.12.02.21266897 doi: medRxiv preprint

The unpublished data supporting the findings of this study are available on the open source Zenodo repository https://zenodo.org/communities/unity-sero-2021?page=1&size=20. ; and all ECDC, WHO Headquarters, Regional and Country Office colleagues who contributed to this work. The authors are alone responsible for the views expressed in this publication and they do not necessarily represent the decisions or policies of the WHO or ECDC.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted December 5, 2021. Enhanced Surveillance of COVID-19 in Scotland: Population-based seroprevalence surveillance Public Health Scotland; 2020 30 September 2020. 30 September 2020. Accessed:01/01/2021. Available from: https://publichealthscotland.scot/publications/enhancedsurveillance-of-covid-19-in-scotland/enhanced-surveillance-of-covid-19-in-scotland-populationbased-seroprevalence-surveillance-30-september-2020/ 65. Sweden PHAo. Påvisning av antikroppar efter genomgången COVID-19 i blodprov från öppenvården (Delrapport 1). 2020. Available from:

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted December 5, 2021. Kunchev A, Stoitsova S. Seroepidemiologic study to detect antibody-mediated immunity against SARS-CoV-2 among residents and healthcare workers in the city of Plovdiv, Bulgaria, weeks 21-24, 2020. Unpublished2020. 93.

De første foreløbige resultater af undersøgelsen for COVID-19 i befolkningen er nu klar. Statens Serum Institut; 2020. 01/01/2021. Available from: https://www.ssi.dk/aktuelt/nyheder/2020/de-forste-forelobige-resultater-af-undersogelsen-forcovid-19-i-befolkningen-er-nu-klar 94.

New preliminary results from the representative seroprevalence study of COVID-19. Statens Serum Institute; 2020. 01/01/2021. Available from: https://files.ssi.dk/notat_foreloebige_resultater_pilotundersoegelse_seropraevalens_COVID-19_29_6_2020 95.

Petersen . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted December 5, 2021. ; https://doi.org/10.1101/2021.12.02.21266897 doi: medRxiv preprint . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted December 5, 2021. ; https://doi.org/10.1101/2021.12.02.21266897 doi: medRxiv preprint Longitudinal study (n=1) Modelling study (n=1) Methodology paper/protocol (n=3) Pre-print of now published article (n=8) Updated information in follow-up paper (n=1) Records identified through database searching (n=1284) 21/10/2020 -31/12/2020

Records identified through other sources (n=18)

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted December 5, 2021. ;

Countries with national-level seroprevalence studies are reported in blue (shade of blue reflects the number of studies conducted in the country/territory). Subnational-level seroprevalence studies are reported as a yellow circle (Size of circle reflects number of subnational studies conducted in the country/territory). Number of studies are listed in boxes under name. Countries with not studies are coloured in grey. The designations employed and the presentation of this material do not imply the expression of any opinion whatsoever on the part of the Secretariat of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers and boundaries. Dotted and dashed lines on maps represent approximate locations for which there may not yet be full agreement.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted December 5, 2021. ; https://doi.org/10.1101/2021.12.02.21266897 doi: medRxiv preprint . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted December 5, 2021. ; https://doi.org/10.1101/2021.12.02.21266897 doi: medRxiv preprint 

World Health Organization; 2021. WHO Coronavirus Disease (COVID-19) Dashboard

Early epidemiological investigations: World Health Organization UNITY protocols provide a standardized and timely international investigation framework during the COVID-19 pandemic. Influenza Other Respir Viruses

Diagnostic Testing for Severe Acute Respiratory Syndrome-Related Coronavirus 2: A Narrative Review

Estimating the extent of asymptomatic COVID-19 and its potential for community transmission: Systematic review and metaanalysis

What do we know about SARS-CoV-2 transmission? A systematic review and meta-analysis of the secondary attack rate and associated risk factors

Occurrence and transmission potential of asymptomatic and presymptomatic SARS-CoV-2 infections: A living systematic review and meta-analysis

Covid-19: US cases are greatly underestimated, seroprevalence studies suggest

Humoral response and PCR positivity in patients with COVID-19 in the New York City region, USA: an observational study

COVID-19 serosurveys for public health decision making. The Lancet Global Health

The PRISMA 2020 statement: an updated guideline for reporting systematic reviews

Rayyan -a web and mobile app for systematic reviews

Meta-analysis of the clinical performance of commercial SARS-CoV-2 nucleic acid, antigen and antibody tests up to 22

Koronaepidemian väestöserologiatutkimuksen viikkoraportti. Finnish Institute for Health and Welfare -THL

Sero-epidemiological Cross-sectional investigation on COVID-19 virus infection in Georgia

Seroprevalence and risk factors of exposure to COVID-19 in homeless people

Weekly Coronavirus Disease 2019 (COVID-19) Surveillance Report: Week 39. Public Health England

Clustering and longitudinal change in SARS-CoV-2 seroprevalence in school children in the canton of Zurich, Switzerland: prospective cohort study of 55 schools

Global seroprevalence of SARS-CoV-2 antibodies: A systematic review and meta-analysis

SARS-CoV-2 seroprevalence worldwide: a systematic review and meta-analysis

Serological evidence of human infection with SARS-CoV-2: a systematic review and meta-analysis. The Lancet Global Health

Global seroprevalence of SARS-CoV-2 antibodies: a systematic review and meta-analysis. medRxiv. 2020:2020.11.17.20233460. 78

Seroprevalence of SARS-CoV-2 IgG antibodies in two regions of Estonia (KoroSero-EST-1)

Seroprevalence of SARS-CoV-2 among adults in three regions of France following the lockdown and associated risk factors: a multicohort study

Seroprevalence and correlates of SARS-CoV-2 neutralizing antibodies from a population-based study in Bonn, Germany

Antibody response using six different serological assays in a completely PCR-tested community after a coronavirus disease 2019 outbreak&#x2014;the CoNAN study

Novel coronavirus epidemic in the Hungarian population, a cross-sectional nationwide survey to support the exit policy in Hungary

Prevalence of asymptomatic SARS-CoV-2-positive individuals in the general population of northern Italy and evaluation of a diagnostic serological ELISA test: a cross-sectional study protocol

A COVID-19 Hotspot Area: Activities and Epidemiological Findings

Prevalence of SARS-CoV-2 infection in the Luxembourgish population: the CON-VINCE study

Experience in studying seroprevalence to SARS-CoV-2 virus in the population of the Irkutsk Region during COVID-19 outbreak

Assessment of the herd immunity to SARS-CoV-2 among the population of the leningrad region during the COVID-19 epidemic

Herd immunity to SARS-CoV-2 among the population in Saint-Petersburg during the COVID-19 epidemic

Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study

Public Health Agency of Sweden

Household Transmission of SARS-COV-2: Insights from a Population-based Serological Survey

Estimates of the rate of infection and asymptomatic COVID-19 disease in a population sample from SE England

CoV-2: seroepidemiological pattern in northeastern Bulgaria

Effectiveness of infection-containment measures on SARS-CoV-2 seroprevalence and circulation from

Seroprevalence of SARS-CoV2 in IBD Patients Treated with Biologic Therapy

RISK FACTOR ANALYSIS FOR SARS-COV-2 SEROPOSITIVITY WITHIN ASSISTED REPRODUCTIVE

Detection of SARS-CoV-2 Antibodies in Kidney Transplant Recipients

Exploratory drilling: how to set up, carry out, and evaluate a seroprevalence study

SARS-CoV-2 Antibody Seroprevalence in Industry Workers in Split-Dalmatia and Šibenik-Knin County, Croatia

High seroprevalence but short-lived immune response to SARS-CoV-2 infection in Paris

Epidemiological study to detect active SARS-CoV-2 infections and seropositive persons in a selected cohort of employees in the Frankfurt am Main metropolitan area

Prevalence of Current and Past SARS-CoV-2 Infections among Police Employees in Poland

Kinetics and seroprevalence of SARS-CoV-2 antibodies in children

Seroprevalence of SARS-CoV-2 antibodies in children: a prospective multicentre cohort study

Mütter-Screening in einem COVID-19-Niedrig-Pandemiegebiet: Bestimmung SARS-CoV-2-spezifischer Antikörper bei 401 Rostocker Müttern mittels ELISA und Immunfluoreszenz-Bestätigungstest

SARS-CoV-2 Seroprevalence Survey in People Involved in Different Essential Activities during the General Lock-Down Phase in the Province of Prato

Severe Acute Respiratory Syndrome Coronavirus 2 Antibodies in Adults in Madrid, Spain

Indicators of past COVID-19 infection status: Findings from a large occupational cohort of staff and postgraduate research students from a UK university

Spike 6SD: 99.9% (95% CI

RBD 3SD: 99.0% (95% CI